Curi Bio announced it has formally established Curi Bio Co., Ltd., a wholly owned subsidiary that will serve as the company’s commercial and operational hub in the Asia-Pacific region, following its full acquisition of South Korea-based Quvit Bio.
The new entity is designed to expand Curi Bio’s direct presence in APAC and strengthen its ability to support customers across South Korea, Japan, and China. Curi Bio said the Korea-based hub is “day-1 ready,” with sales, R&D, and operational capabilities intended to provide localized technical and commercial support across the company’s product and services portfolio.
As part of the move, Curi Bio is integrating Quvit Bio’s assets and team, adding regional expertise spanning sales and business development, hardware and software engineering, and life science tools. The company also said the local operations footprint will help reduce delays tied to international logistics for deliveries of cells, media, hardware, and consumables.
Curi Bio added that Dr. Wonil Lee has been appointed vice president of research and commercialization and will represent Curi Bio Co., Ltd. as a central point of contact for current and prospective customers in the region.
Curi Bio develops human stem cell-based platforms for drug discovery and development. Its integrated platform, The Curi Engine, combines human iPSC-derived cell models, tissue-specific biosystems, and AI/ML-enabled phenotypic screening data to help biopharmaceutical partners generate human-relevant preclinical data and reduce reliance on animal models.
KEY QUOTE:
“Establishing direct operations in Korea and integrating Quvit’s talented team is a pivotal moment that accelerates our global strategy. We can now offer localized technical and sales support for our existing customer base across South Korea, Japan, and China while lowering the access barrier to Curi’s industry-leading NAM technology for all drug developers in the region.”
Dr. Nicholas Geisse, CEO, Curi Bio
